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Pancreatic ductal adenocarcinoma (PDAC) is one of the few cancer types where the 
5-year survival rate shows no improvement.
Despite conflicting evidence, the majority of data points to an essential role for autoph-
agy in PDAC growth and survival, in particular constitutively activated autophagy, can 
provide crucial fuel to PDAC tumor cells in their nutrient-deprived environment.
Autophagy, which is required for cell homeostasis, can both suppress and promote 
tumorigenesis and tumor survival in a context-dependent manner. Protein by protein, 
the mystery of how PDAC abuses the cell’s homeostasis system for its malignant growth 
has recently begun to be unraveled. In this review, we focus on how autophagy is 
responsible for growth and development of PDAC tumors and where autophagy and 
the mechanisms controlling it fit into PDAC metabolism. Understanding the range of 
pathways controlling autophagy and their interplay in PDAC could open the way for new 
therapeutic avenues.
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iNTRODUCTiON
Pancreatic cancer is a disease in which malignant cells originate in pancreatic tissue, leading to 
over 200,000 deaths per year worldwide—making pancreatic cancer the ninth leading cause of 
death from cancer (1). Eighty-five percent of pancreatic cancer cases are pancreatic ductal adeno-
carcinomas (PDACs), and there is currently no effective screening tool to detect early malignant 
or premalignant tumors. This makes PDAC one of the most deadly common cancers, as diagnosis 
is most likely to be at an advanced stage, with metastatic or locally advanced disease (2). Median 
patient survival is only 6–9 months (3) and only about 4% of patients live 5 years after diagnosis (4).
Defining features of PDAC include a high rate of KRAS activating mutations (>90%), a reprogram-
ming of cellular metabolism, a hypervascular and hypoxic microenvironment, and susceptibility to 
both local invasion and metastasis (2). Therapeutic resistance of PDAC to radiotherapy, targeted 
agents, and chemotherapy means that new therapeutic avenues are urgently needed. One avenue 
would be to target the autophagic pathway as a number of studies have linked autophagy to PDAC 
survival and progression.
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved membrane-
mediated process that delivers cytoplasmic constituents to lysosomes for degradation and component 
recycling. This complex process is mediated by at least 18 autophagy genes (Atg genes) in mammals 
(5). Upon autophagy induction triggered by cell stress, double membrane autophagosomes form 
and engulf cytosolic proteins and damaged organelles, either through a non-selective process or a 
selective receptor mediated autophagy, such as mitophagy (6). Autophagy initiation is controlled by 
the ULK kinase complex and the VPS34 phosphoinositol-3-phosphate (PtdIns3P)-kinase complex 
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containing Beclin-1, which integrate stress signals from the mTOR 
complex 1 (mTORC1). When mTORC1 activity is inhibited, the 
ULK and the Beclin-1 complex translocate to the initiation site 
marked by ATG9 (7). The production of PtdIns3P by the Beclin-1 
complex allows binding of WIPI2, recruitment of ATG12-5-16, 
and lipidation of the LC3/GABARAP family (8). Lipidated LC3 
(LC3-II) is required for autophagosome formation, and detection 
of LC3-II by immunoblotting or immunofluorescence is the most 
established method of monitoring autophagy.
In normal conditions, autophagy is a homeostatic mechanism 
that serves to degrade damaged proteins and organelles that may 
diminish cellular fitness and integrity. The levels of autophagy can 
also be changed in response to a variety of intracellular and extra-
cellular stresses, such as starvation, ER stress, hypoxia, oxidative 
stress, and pathogen invasion. The role of autophagy in cancer 
is complex with both tumor-survival and tumor-suppressive 
roles, which are dependent on tumor type, stage, and genetic 
lesions. Autophagy is thought to inhibit malignant transforma-
tion under normal conditions and is required for anticancer 
immunosurveillance (9). However, autophagy in cells which are 
already malignant frequently supports tumor progression and 
anticancer therapy resistance, by providing a means for cells to 
survive intracellular and extracellular stress (9).
Autophagy is tightly regulated starting from transcriptional 
activation to posttranslational protein modification (10), and 
the regulation of autophagy in PDAC is gradually becoming 
elucidated. Transcriptional control of autophagosome–lyso-
some function has been shown to drive PDAC metabolism (11), 
whereas starvation-induced vacuolar protein 1 (VMP1) expres-
sion in pancreatic acinar cells drives early autophagy through 
VMP1 association with the early autophagic structures on the 
ER membrane (12, 13). Autophagy inhibition or loss has been 
shown to lead to tumor regression in PDAC xenograft models 
and death in PDAC cell lines (14). Autophagy supports PDAC 
cell survival by a range of mechanisms, including autophagic 
secretion of alanine by pancreatic stellate cells (PSCs) for tumor 
metabolism (15) and prevention of ER stress (16). The well docu-
mented role of autophagy for survival of PDAC and the potential 
for therapy through autophagy modulation has been explored 
in PDAC cell lines, where autophagy blockage has been shown 
to reduce chemoresistance (14). In one study involving a small 
number of human patients, inhibition of autophagy did not show 
any significant therapeutic effect (17).
The focus of this review will be the role of autophagy in PDAC, 
a cancer type in which extensive evidence currently points to a 
dependence on autophagy for tumor growth, development, and 
metabolism (14, 18), although there are also studies highlighting 
autophagy-independent PDAC cell line and tumors (19, 20).
DUAL ROLe OF AUTOPHAGY iN CANCeR
It is now accepted that autophagy can suppress or promote tumo-
rigenesis and tumor survival depending on cellular context and 
stage in tumor development, this characteristic is referred to as a 
“double-edged sword” (21) (Figure 1).
Defects in the autophagic machinery in mouse cancer models 
have been connected to malignant transformation in a number 
of studies, and indeed, the tumor-suppressive properties of 
Beclin-1 provided the first evidence of this (22). More recently, 
mice heterozygous for activating molecule in Beclin-1-regulated 
autophagy (AMBRA1) were also shown to have an increased rate 
of tumorigenesis (23). The scaffold protein AMBRA1 was shown 
to promote the binding of protein phosphatase 2A to the c-Myc 
transcription factor and, when mTOR is inhibited, causes c-Myc 
to be dephosphorylated consequently followed by a reduction in 
cell division (23). Other mechanisms through which autophagy 
functions in an oncosuppressive role include protection of the 
cell from mutagenic reactive oxygen species (ROS) accumula-
tion, DNA damage, genomic instability, and oncogenic proteins, 
hyperactivation of which activates autophagy (9). While this 
suppressive function typically allows the cells to survive, pro-
longed autophagy activation may result in caspase-independent 
autophagic-programmed cell death (24). Autophagic cell death is 
poorly defined but is associated with autophagosome formation 
and depends on autophagy proteins, although it is controversial 
whether cells truly die via autophagy, particularly as there are 
no distinct markers of the process (25). Autophagy may also 
contribute to oncogene-induced senescence, demonstrated by 
depletion of ATG5 by shRNA which inhibits oncogene-induced 
senescence in human fibroblasts (26). There is a growing body of 
evidence showing that defects in autophagic machinery prevent 
malignant cell proliferation, for example, metastatic carcinoma 
cell lines where Beclin-1 or ATG5 is downregulated are unable to 
survive (27), and siRNA depletion of the essential autophagy gene 
ATG7 enhances apoptosis in colon cancer cells (28).
In contrast, autophagy may allow established tumors to 
survive and progress by reducing their sensitivity to stress and 
cell death signals. Enhanced autophagic response in advanced 
human tumors correlated with an invasive phenotype and poor 
prognosis (29). Autophagy also supports tumor cell survival by 
increasing ATP levels during hypoxia, nutrient deprivation, and 
detachment from the extracellular matrix, all of which may occur 
in tumors and would usually result in cell death (9). A number 
of anticancer therapies have been shown to induce autophagy in 
human cancer cell lines (30), which may cause cells to become 
resistant to the therapy, and autophagy inhibition can re-sensitize 
previously resistant cells to therapy (31).
In summary, the role of autophagy in cancer appears to change 
during tumor progression. Autophagy protects healthy cells from 
malignant transformation by maintaining cellular homeostasis 
and normal metabolism, but after malignant transformation, 
when presumably autophagy has been suppressed, restoration of 
autophagy promotes tumor progression, invasion, and metasta-
sis (9). The pro-survival role of autophagy in tumors has been 
explored as a potential therapeutic target in a number of cell-
based studies and clinical trials.
MOLeCULAR CONTROL OF 
AUTOPHAGY iN PANCReATiC 
CANCeR AND iTS DeveLOPMeNT
Autophagy is crucial for maintaining cellular homeostasis 
and has a dual role in cancer as discussed above. It is therefore 
FiGURe 1 | Summary diagram indicating the stimuli that induce autophagy in pancreatic ductal adenocarcinoma (PDAC) and regulation of 
autophagy through different stages of cancer progression.
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important to understand autophagy regulation as a degradation 
and stress-control pathway. The TOR and RAS–cAMP–PKA sign-
aling cascades negatively regulate autophagy and sense nutrient 
deprivation (which activates autophagy), although details on how 
multiple signaling mechanisms coordinate in order to control 
autophagy are not fully understood (32) (Figure 1). Molecular 
control of autophagy has been widely studied, and the process is 
tightly regulated at various levels (10).
One of the levels of autophagy regulation is transcriptional 
control. Transcription of LC3 is upregulated during starvation 
in mammalian cells (10), a process dependent on the FoxO3 
transcription factor (33). Epigenetic changes have also been 
shown to regulate autophagy, such as the hyperacetylation of 
histones through histone deacetylase inhibitor treatment, which 
activates autophagy (34). Posttranslational modification of the 
autophagy machinery includes phosphorylation of Beclin-1 in 
response to autophagic stimuli, which is required for maximal 
autophagy (35).
Despite the accumulation of information on molecular 
control of autophagy, evidence is just emerging showing these 
mechanisms (transcriptional, epigenetic, or posttranslational) 
controlling autophagy are active in PDAC. The evidence on 
autophagy control in PDAC will be summarized for the purpose 
of this review.
Molecular Control of Autophagy  
in PDAC Survival
A major route in the development of PDAC is through acinar 
cell damage and dysfunction. Pancreatic acinar cells produce and 
secrete digestive enzymes and proteases, which require a very 
high protein biosynthetic rate and an extensive rough endoplas-
mic reticulum network. Consequently, acinar cells are prone to 
accumulation of misfolded proteins and ER stress (36, 37). The 
latter can be involved in the pathogenesis of pancreatitis, which 
in turn causes inflammation of the exocrine pancreas that may 
lead to development of PDAC (38). This is particularly likely in 
the case of chronic pancreatitis (39).
Autophagy is required for the maintenance of acinar cell 
physiology, as demonstrated by in vivo loss of ATG7 in pancreatic 
epithelial cells leading to pronounced acinar cell damage and 
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loss followed by chronic pancreatitis (16). Primary acinar cells 
depleted of ATG7 displayed an impaired autophagic canonical 
flux as LC3-I and p62 protein levels were elevated. Impaired 
autophagy can lead to an increase in misfolded proteins that 
undergo ubiquitination and are bound by p62, leading to ER 
stress and mitochondrial damage (40). Conditional ATG7 knock-
out mice, in which ATG7 was lacking in all pancreatic epithelial 
cells, displayed an increase in damaged mitochondria and ER 
stress, resulting in accumulation of ROS in the pancreata. To 
counteract these disruptive processes, ATG7-depleted primary 
acinar cells and pancreata upregulate the transcription nuclear 
factor erythroid 2-related factor 2 (NRF2), which can stimulate 
an antioxidative response (16, 41).
A way in which autophagy in acinar cells may be controlled 
is through VMP1, which triggers the formation of LC3 positive 
vacuoles when stably expressed in the pancreatic acinar cells 
of transgenic mice (12). Cell starvation and mTORC1 inhibi-
tion induce VMP1 expression (12), and VMP1 is thought to 
function through interaction with Beclin-1 and recruitment of 
the PtdIns3P-kinase complex at the phagophore (42). VMP1 
transiently localizes with early autophagic structures on the ER 
membrane (13) and co-localizes with ULK1 at early autophagic 
structures (13). Furthermore, RNAi experiments in PANC1 cells 
show that oncogenic KRAS requires VMP1 to induce autophagy. 
In PDAC cells, VMP1 is upregulated via a KRAS–PI3K–AKT1–
GLI3-p300 pathway (43). This is of particular interest given that 
VMP1 was originally identified in rats as a pancreatitis-induced 
protein restricted to acinar cells (44), so expression of this protein 
is likely to be an autophagy regulator in PDAC.
As discussed above, accumulation of misfolded proteins and 
ER stress can be involved in pathogenesis of pancreatitis. ROS 
generation, which has been shown to regulate autophagy, might 
contribute to this process (45). In PDAC cell lines, ROS inhibition 
with an antioxidant significantly reduced basal autophagy levels 
and, conversely, autophagy inhibition resulted in an increase in 
ROS levels, confirming a cross-regulation of ROS and autophagy 
in PDAC (14). The role of ROS and autophagy in PDAC may 
be biphasic—during early stages of cancer low autophagy levels 
allow ROS to promote pro-tumorigenic genomic instability 
required for transformation, whereas in more progressed PDAC 
cells, autophagy protects the cells from cytotoxic ROS accumula-
tion (14). This has been demonstrated by an increase in markers 
of double-strand breaks such as 53BP1 foci in PDAC cells where 
autophagy is inhibited, and this DNA damage in PDAC is thought 
to allow increasing tumor growth (14).
Molecular Control of Autophagy in PDAC 
Development
There is a range of evidence showing that PDAC tumors have con-
stitutively activated autophagy and are dependent on autophagy 
for survival and development. Measurement of LC3 puncta and 
LC3-II levels in PDAC cell lines shows elevated basal autophagy 
levels compared to non-cancerous pancreatic cells and other 
cancer cell lines (14). Immunohistochemistry analysis of samples 
from a range of human pancreatic tumors has shown an increase 
in autophagy levels during the progression from premalignant 
pancreatic intraepithelial neoplasms (PanINs) to more advanced 
PDAC (14). The role of autophagy in PDAC progression was 
probed further by the use of the chloroquine (CQ), which raises 
the lysosomal pH and thereby inhibits autophagy, to treat mice 
with advanced PanIN or PDAC, which suppressed tumor growth 
in vivo (14).
However, in a separate mouse study, it has been shown that 
autophagy deficiency increases PanIN development and tumor 
initiation, although it makes PanIN progression to PDAC 
less likely (46). This is supported by evidence showing that 
autophagy-deficient ATG7−/− mice show enhanced RAS-driven 
PanIN formation but do not develop PDAC (20).
The functions of the RAS oncogene and TP53 tumor suppres-
sor in tumorigenesis have been described in detail elsewhere, and 
aberrations of both of these proteins appear to be cooperative in 
their contribution to malignancy (47). As well as the high rate 
of KRAS activating mutations, sequence analysis has shown that 
PDACs demonstrate a mixture of tumor suppressor gene muta-
tions, with TP53 being mutated or inactivated in 75% of PDAC 
and mutant TP53 being shown to drive pancreatic cancer (48). 
Autophagy inhibition by CQ treatment or RNAi has been shown 
to inhibit growth of PDAC cell lines harboring TP53 mutations. 
Furthermore, patient-derived xenografts with TP53 mutations 
grow slower after autophagy inhibition (46).
In contrast, TP53 status has been shown to determine the 
role of autophagy in tumor development in mice KRAS mutant 
pancreatic tumors, where PDAC formation is accelerated by 
autophagy inhibition in cases where TP53 is absent (20). This 
may be because TP53-deficient tumors and cell lines have lower 
numbers of autophagosomes, so their viability is not dependent 
on the process (20). This indicates that autophagy is not always 
critical to PDAC tumor development.
Another study indicates that autophagy is dispensable for 
growth of KRAS mutant tumors and cell lines (19). Forty-seven 
human cancer cell lines were treated with the CQ derivative Lys01 
or shRNA to remove autophagic machinery components such as 
ATG7, revealing that KRAS-mutated cells are no more dependent 
on autophagy than their wild-type counterparts (19). This was 
supported by in  vivo experiments where autophagy inhibition 
did not reduce growth of a KRAS mutant tumor derived from 
the PDAC cell line Panc10.05 (19). These findings raise questions 
regarding the assumption that inhibition of autophagy reduces 
cell growth and viability of KRAS mutant PDAC cells and could 
mean that the function of autophagy is to support tumor growth 
through host tissues, such as cancer-associated fibroblasts (49).
Hypoxia-induced Autophagy in PDAC
Preexisting vasculature of normal tissue has been shown to be 
insufficient to support the requirements of tumors for nutrients 
and oxygen, and in particular, the pancreatic tumor microenvi-
ronment has been found to be hypoxic (50). Higher tumor levels 
of hypoxia as measured by hypoxia-inducible factor 1α (HIF-1α) 
expression have been shown to correlate with poor prognosis in 
patients with PDAC (51, 52).
The cellular response to hypoxia may contribute to elevated 
basal autophagy levels in PDAC, as autophagy can be induced 
by hypoxia in several ways. First, HIF-1α has been shown to 
upregulate Bcl-2/adenovirus E1B 19-kDa protein-interacting 
5New et al. Autophagy in Pancreatic Cancer
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 28
protein 3 (BNIP3) and BNIP3 like protein (BNIP3L). BNIP3 
and BNIP3L subsequently disrupt the Bcl-2–Beclin-1 complex 
in an mTOR-independent way, which induces autophagy (53). 
This mechanism has been demonstrated in various cancer cell 
lines, including prostate cancer and salivary adenoid cystic car-
cinoma, and we speculate that this process may occur in PDAC 
(54, 55). In contrast, another study suggests hypoxia-induced 
autophagy in tumor cells is dependent on AMP-activated 
protein kinase and mTOR, thus excluding a role for HIF-1α, 
BNIP3, and BNIP3L (56). In a hypoxic tumor microenviron-
ment, the unfolded protein response can facilitate autophagy. 
This mechanism involves the PKR-like endoplasmic reticulum 
kinase-activating transcription factor 4 (ATF4) pathway. 
ATF4 is able to bind a cyclic AMP response element binding 
site in the LC3B promoter inducing LC3B transcription (57). 
This ATF4-mediated transcriptional LC3B induction results 
in replenishment of LC3B levels during extended periods of 
hypoxia characterized by high autophagic flux (58).
Evidence for the connection between autophagy and hypoxia 
in PDAC tumors is high levels of LC3, which has been shown to 
be associated with the hypoxic marker carbonic anhydrase IX at 
the peripheral area of the pancreatic cancer tissue (59). Under 
intermittent hypoxia, pancreatic cancer cells demonstrated 
enhanced invasive ability and increased levels of the cancer stem 
cells (CSC) marker CD133. In these cells, enhanced autophagy 
was correlated with elevated HIF-1α levels. The metastatic ability 
and epithelial-to-mesenchymal transition of pancreatic CSC was 
also associated with HIF-1α and autophagy (60). These findings 
are consistent with a previous report showing autophagy to 
increase survival and migration of pancreatic tumor-initiating 
CSCs under hypoxic conditions (61). Recent research in the 
pathways underlying hypoxia in PDAC revealed that hypoxia 
induces ROS production which subsequently inhibits the pAKT/
mTORC1 pathway, inducing autophagy. This process results in a 
decrease in MUC4 protein levels (an oncogenic transmembrane 
protein expressed during the early preneoplastic stage). MUC4 
degradation decreases growth and survival, potentially providing 
other stressed cells with required metabolites (62).
In conclusion, although there is significant evidence linking 
hypoxia and autophagy in PDAC and the translational relevance 
of this connection, the precise mechanism for hypoxia-induced 
autophagy in PDAC is not fully elucidated.
MOLeCULAR PATHwAYS iNvOLveD iN 
AUTOPHAGY AND iTS iMPACT ON 
PANCReATiC CANCeR MeTABOLiSM
Autophagy plays a major role in PDAC metabolism, although not 
all pathways involved in activating and reprogramming autophagy 
in this context are fully elucidated. Autophagy in PDAC can be 
seen as part of a broader transcriptional program that coordinates 
lysosome function and nutrient sensing by the MiT/TFE subclass 
of basic helix–loop–helix transcription factors including TFE3, 
MITF, and TFEB, ensuring sufficient levels of intracellular amino 
acids (11). PDAC cells display an increased lysosomal biogenesis 
accompanying their expanded autophagosome compartment. 
In normal cells under nutrient stress, biogenesis of autophagy–
lysosome proteins is under control of the MiT/TFE transcription 
factors (63). RNAseq data across 10 tumor types revealed a high 
relative expression of these transcription factors in PDAC (11). 
MiT/TFE proteins act selectively in PDAC cells to regulate a 
broad autophagy–lysosome program under basal conditions. 
Despite displaying intact mTORC1 signaling, which phospho-
rylates MiT/TFE proteins in fed conditions in non-PDAC cells 
and ensures their cytoplasmic retention (64), PDAC cells show 
constitutive nuclear localization of each MiT/TFE protein. The 
cytoplasmic retention mechanism of MiT/TFE in PDAC cells is 
overwritten by importin-8 (IPO8), a member of the importin-β 
family of nucleocytoplasmic transporters (65). In PDAC cells, in 
contrast to non-PDAC cells, IPO8 binds TFE3 resulting in its 
nuclear translocation and upregulation of its transcriptional pro-
gram regardless of the nutritional condition (11). Endogenous 
binding of IPO8 to MITF or TFEB was not shown; however, a 
combinational depletion of IPO8 and its homolog IPO7 in PDAC 
cells decreased MITF and TFEB protein levels.
Depletion of MiT/TFE proteins across several PDAC cell lines 
revealed a regulatory role for MiT/TFE proteins in autophagic 
flux and lysosomal catabolism. This enables efficient processing 
of cargo from autophagy and macropinocytosis. Thus, the MiT/
TFE protein system provides PDAC cells with both intracellular 
and extracellular nutrient supplies (11). In nutrient-depleted 
conditions, PDAC cells rely on the autophagy–lysosome system 
to maintain intracellular amino acid pools. In vitro, silencing of 
MiT/TFE proteins impaired growth of PDAC cells. TFE3 and 
MITF were also required for in vivo xenograft growth of several 
PDAC cell lines (11).
In summary, overriding MiT/TFE inactivation by mTORC1 via 
IPO8-driven nuclear import enables PDAC cells to maintain their 
intracellular amino acid pool by activation of both autophagy and 
lysosomal catabolism (Figure 2) (11). This system resembles the 
constitutive nuclear import of the pro-oncogenic protein eIF4E 
(a downstream target of mTORC1) in acute myeloid leukemia 
patients by IPO8 (66) and might be a general mechanism used by 
several cancer types.
In addition to MiT/TFE-regulated autophagic-lysosomal 
catabolism, PDACs are also dependent on mitochondrial 
oxidative phosphorylation for their energy supply. Using an 
inducible mouse model of mutated KRAS in a TP53 heterozygous 
background, Viale et al. showed that repression of mutant KRAS 
resulted in regressed growth of implanted cells isolated from 
primary tumors, followed by a relapse after 4–5 months (67). This 
suggests that a fraction of dormant tumor cells survive oncogene 
ablation [surviving cells (SCs)]. SCs may possess CSC character-
istics as only CD133+ CD44high cells were able to avoid apoptosis 
(67–69). Transcriptomics analysis showed genes involved in the 
mitochondrial electron transport chain (ETC), lysosome activity, 
and autophagy are upregulated in SCs. A hyperactive ETC and 
increased ROS production are hallmarks of SCs. SCs operate 
close to their maximum respiratory chain capacity and fail to 
increase glycolysis upon oxidative phosphorylation inhibition in 
a manner sufficient to maintain ATP production. Furthermore, 
SCs seem to rely more on pyruvate and palmitate than glucose 
and glutamine to generate TCA intermediates (67). This is 
FiGURe 2 | Overview of the molecular pathways involved in autophagy and its impact on pancreatic cancer metabolism. Constitutive nuclear import of 
MiT/TFE proteins by importin-8 (IPO8) upregulates the autophagic-lysosomal machinery in pancreatic ductal adenocarcinoma (PDAC) (11). Autophagy fuels the TCA 
cycle by amino acid production, shifting the usage of glucose from glycolysis to Ser/Gly biosynthesis (67). This mechanism is further strengthened by pancreatic 
stellate cells (PSCs) secreting alanine upon autophagy stimulation by unknown PDAC factors (15). Furthermore, the necessity for palmitate feeding oxidative 
phosphorylation is upregulated in PDAC. Citrate, produced during the TCA cycle, is used for fatty acid biosynthesis, leading to lipid droplet formation and 
microlipophagy (67). This process, together with the macropinocytotic uptake of extracellular proteins, amplifies the autophagic system in PDAC (11, 67). Arrows 
and names in bold mark an upregulated pathway in PDAC.
6
New et al. Autophagy in Pancreatic Cancer
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 28
consistent with previous data reporting activation of anabolic 
glucose and glutamine metabolism in PDAC by oncogenic KRAS 
(70, 71).
The dependence on oxidative phosphorylation by SCs for 
their survival was demonstrated by oligomycin treatment of 
a tumor regression mouse model. Tumors were grown in a 
mutant KRAS/TP53 heterozygous-inducible mouse model and 
regressed upon doxycycline withdrawal. When reintroducing 
mutant KRAS, 25% of oligomycin-treated mice survived longer 
than 60  days while vehicle-treated mice survived on average 
15  days (67). Mitochondrial respiration would thus make an 
attractive druggable target to eradicate SCs in PDAC. The ETC 
dependence of SCs is consistent with previous reports showing 
both normal and leukemic stem cells rely on mitochondrial 
respiration (Figure 2) (72).
The role of autophagy in pancreatic cancer metabolism is 
not restricted to just PDAC cells, but cells surrounding tumors 
also use autophagy for their energy supply. The surrounding 
environment heavily influences PDAC metabolism, for example, 
the stroma enveloping PDAC cells impairs vascularization of 
TABLe 1 | Overview of autophagy-related pancreatic ductal adenocarcinoma (PDAC) therapies currently being tested in clinical trials listed on the US 
website http://Clinicaltrials.gov.
Aim Agent Trial design NCT number





Determine the ability of HCQ to improve a pre-operative regime of 




Randomized phase II NCT01978184





Determine whether a combinational therapy of HCQ/radio therapy/






New et al. Autophagy in Pancreatic Cancer
Frontiers in Oncology | www.frontiersin.org March 2017 | Volume 7 | Article 28
tumors leading to a hypoxic, nutrient-poor environment (73). 
Recently, a new role has been described for stroma-associated 
PSCs in governing PDAC metabolism. When treating PDAC 
cells with conditioned medium from a human PSC cell line, the 
oxygen consumption ratio in PDAC cells increased independ-
ent of the presence of serum (15). This effect was attributed to 
alanine secreted by PSCs. The increase in intracellular alanine 
concentrations in PDAC cells by PSC-derived alanine could even 
be further induced by silencing of GPT1, the alanine transami-
nase responsible for transamination of alanine to form pyruvate 
and glutamate. Alanine-derived pyruvate did not contribute 
to glycolytic intermediates but was used in mitochondria as a 
major source for the TCA cycle as citrate was the main recipient 
of carbon originated from alanine (15). This alanine-derived 
carbon would then further fuel fatty acid biosynthesis and could 
supplant glucose-derived carbon in TCA cycle metabolism, 
enabling glucose to be used for additional biosynthetic functions 
(for example, serine/glycine biosynthesis) (15, 71).
Surprisingly, treatment of PSCs with PDAC-conditioned 
medium significantly increased autophagic flux in PSCs and 
depletion of ATG5 and ATG7 in PSCs abolished alanine secre-
tion. These findings reveal a two-way intra-tumor metabolic 
crosstalk in which PDAC signals to PSCs resulting in autophagy 
induction in the latter, followed by PSC-derived alanine secretion 
which can fuel the TCA cycle in PDAC. This process is of sig-
nificant importance under low-nutrient conditions, which mimic 
the nutrient-deprived PDAC environment. In vivo, co-injection 
of PDAC cells with autophagy-impaired PSCs decreased tumor 
growth and kinetics, also in orthotopic assays.
An unresolved question in the PDAC–PSC crosstalk is how 
PDAC stimulates autophagic flux in PSCs (Figure  2). Just as 
autophagy inhibitors in PSCs may be effective, this could be a 
new avenue for therapeutic intervention, restraining PDAC 
growth and sensitizing tumors to chemotherapy. One possible 
mechanism may be regulated by TGF-β1 secretion from PDAC. 
Activation of PSCs by TGF-β1 transforms them to an activated 
myofibroblast-like phenotype where synthesis of excessive 
amount of extracellular matrix proteins causes fibrous tissue 
formation (74). Furthermore, TGF-β1 was shown to induce 
autophagy in hepatic stellate cells (75) so a similar mechanism 
may be at play in PSCs although other cytokines secreted by 
PDAC cells could also be involved in this process.
Future therapies targeting the metabolism of PDAC are likely 
to be directed toward fighting a multifront battle. The autophagic 
component is one important aspect of this battle but will need to 
be part of a combined approach to drain or disrupt PDAC energy 
supplies.
POTeNTiAL FOR PDAC THeRAPY 
THROUGH AUTOPHAGY MODULATiON
Autophagy inhibition is a promising avenue for therapeutic 
treatment of PDAC. One of the first clinical trials aimed at 
inhibiting autophagy in PDAC used hydroxychloroquine (HCQ), 
which did not demonstrate a significant therapeutic effect as a 
monotherapy (17). However, the HCQ doses tested in this study 
may have been inadequate to consistently inhibit autophagy, and 
patients tested were suffering from previously treated metastatic 
tumors. It should be noted at this point that the antiproliferative 
effects of CQ were shown to be autophagy independent as both 
ATG7-deficient and -proficient cells were equally sensitive to CQ 
(19). This implies that data from clinical trials involving CQ as 
an autophagy inhibitor should be interpreted with caution. More 
promising were results from Yang et al. who showed CSCs in vivo 
were more susceptible to gemcitabine treatment upon autophagy 
inhibition, and combined treatment was more effective than 
either agent alone in preventing pancreatic tumor formation (18). 
In addition, as Viale et al. proved in SCs that ETC, lipophagy, and 
autophagy are all critical for the survival of SCs (67), inhibition of 
autophagy alone still leaves alternative pathways for PDAC energy 
production. Thus, the potential efficacy of a monotherapy inhibit-
ing autophagy in PDAC is low, and combinational therapies are 
preferential. An overview of autophagy-related PDAC therapies 
currently being tested in clinical trials listed on the US website 
http://Clinicaltrials.gov can be found in Table 1.
Investigation is ongoing into a number of possibilities for 
combinational PDAC treatment involving autophagy inhibition. 
MAPK and NF-κB inhibition could be a promising strategy. 
PANC1 and MIA-PaCa-2 PDAC cell lines were treated with 
U0126 (a MAPK inhibitor) or caffeic acid phenethyl ester (CAPE, 
an NF-κB inhibitor), producing a strong inhibition of tumor 
cell growth without inducing apoptosis. Autophagy inhibition 
by (3-MA, an inhibitor of PI3K, which blocks autophagosome 
formation) followed by PDAC treatment with U0126 or CAPE 
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caused a significant apoptotic response (76). A combinational 
treatment including MAPK/NF-κB/autophagy inhibitors might 
thus be an interesting avenue.
More evidence supporting a combinational therapy involving 
NF-κB inhibitors was provided by Yang et al. (18). This study also 
emphasizes the need for reliable prognostic markers for PDAC. 
The high metastatic potential and resistance to chemotherapy 
and radiation therapy in several cancers have been linked 
to CSCs (77–79). Presence of CSCs is associated with poor 
outcome for patients diagnosed with pancreatic cancer (80). 
A putative marker for CSCs, other than the aforementioned 
CD133 and CD44, is aldehyde hydrogenase 1 (ALDH1) (81). 
Another marker associated with poor prognostic outcome in 
several cancers is osteopontin (OPN), a secreted glycoprotein 
able to interact with CD44 and activate several downstream 
signaling pathways such as growth factor receptor signaling via 
PI3K/AKT, NF-κB, and MEK/ERK (82–85). High expression of 
LC3 combined with high levels of ALDH1 is associated with 
shorter overall survival and disease-free survival in pancreatic 
cancers patients, making coexpression of LC3/ALDH1 a valuable 
prognostic PDAC marker (18). Autophagy inhibition by silencing 
of ATG5, ATG7, or Beclin-1 in vivo rendered tumors markedly 
more susceptible to gemcitabine treatment. A combined treat-
ment of CQ and gemcitabine was more effective than either 
agent alone in preventing pancreatic tumor formation in  vivo 
(18). Autophagy blockade boosted the susceptibility of pancreatic 
CSCs to gemcitabine and thus enhanced the efficacy of gemcit-
abine against pancreatic cancer. OPN was found to upregulate 
CSC activity by activating autophagy. OPN can exert its functions 
by triggering the NF-κB, MEK/ERK, and p38 MAPK in PDAC 
cells. Pretreatment with BAY 1170–82, an NF-κB inhibitor, could 
effectively block the OPN-mediated LC3-II increase in PANC1 
cells (18). A role for OPN is also found in breast cancer, where 
its expression associates with cancer aggressiveness. Depletion 
of OPN in breast cancer cells inhibited the class I PI3K/AKT/
mTOR pathway, promoted expression of LC3 and Beclin-1, and 
increased apoptosis (86). Pharmacological autophagy and NF-κB 
inhibition have not been tested in this context.
KRAS was considered another interesting prognostic marker 
for PDAC. As oncogenic KRAS has been described as a contribut-
ing factor in PDAC addiction to autophagy, it was suggested that 
the mutation status of RAS could identify patients who would 
be more susceptible for HCQ treatment (87). This biomarker 
avenue turned out not to be beneficial for patient selection as 
oncogenic KRAS did not always promote autophagy (88). As 
mentioned above, oncogenic KRAS can have both stimulating 
and repressive effects on autophagy, and these differing effects 
are tumor cell-specific and context-dependent. Considering 
CQ sensitivity, KRAS activation rendered some cell lines more 
susceptible to CQ while others became more resistant (88). This 
is in line with the findings of Rosenfeldt et al. who suggest that 
in the absence of TP53, autophagy is no longer required for 
KRAS-mediated tumor development in PDAC, although this 
study does not indicate that p53 status predicts the response 
to anti-autophagic therapy for a developed tumor (20). Thus, 
the quest for suitable biomarkers identifying PDAC patients 
susceptible to autophagy inhibition is currently still ongoing.
CONCLUSiON AND FUTURe DiReCTiONS
Autophagy has roles both in protection from malignant trans-
formation and in promotion of tumor progression and survival. 
In the case of PDAC, a significant body of evidence points to a 
pro-tumorigenic autophagy role, where the constitutive activa-
tion of this process allows cell survival and promotes metabolism.
The mechanisms for this are diverse and require consideration 
of both the tumor itself and the surrounding tissue, such as stroma-
associated PSCs, which provide metabolic support for the tumor 
by secreting alanine through cancer cell-stimulated autophagy, 
hence fueling the TCA cycle, Ser/Gly biosynthesis, and fatty acid 
synthesis in PDAC cells (15). Within the PDAC cells, it is thought 
that autophagy is constitutively active and is regulated through 
transcriptional control (11) and ROS-related signaling (45). 
Surrounded by a stressful environment, therefore, one way PDAC 
cells can upregulate their energy production components to fuel 
their expansion and migration is through autophagy. Autophagic 
genes and flux are upregulated in PDAC, as are the lysosomal and 
oxidative phosphorylation systems (67). MiT/TFE proteins play a 
crucial role in the basal transcriptional upregulation of autophagy 
in PDAC (11). Furthermore, upregulated autophagy is important 
for survival of these cells, as demonstrated by studies where 
autophagy is either pharmacologically or genetically impaired, 
resulting in loss of viability in PDAC cell lines and pancreatic 
cancer xenograft regression (14). PDAC progression has also 
been shown to rely on autophagy, although this appears to be 
dependent on TP53 status. In cases where TP53 is absent, tumors 
and cell lines are actually accelerated by autophagy inhibition 
(20), highlighting the need for biomarkers to report autophagy 
inhibition in PDAC.
Pancreatic cancer is a cancer of unmet need (89). The 
requirement of many pancreatic cancers for constitutively 
activated autophagy makes targeting this pathway an attractive 
new therapeutic avenue. However, due to the various feedback 
loops, crosstalk and parallel energy supply systems in PDAC, it 
might be challenging to impair PDACs’ energy metabolism by 
autophagy inhibition on its own. Early clinical trials have shown 
that autophagy inhibition as a monotherapy may not be sufficient 
(17), but clinical trials involving combination treatment of an 
autophagy inhibitor and chemotherapy treatments are ongoing. 
In this light, the development of new, more effective upstream 
autophagy inhibitors of autophagy also has great potential.
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